Schrödinger ends development of blood cancer drug after patient deaths
Schrödinger is ending development of the CDC7 inhibitor as both a monotherapy and combination.
15 August 2025
15 August 2025
Schrödinger is ending development of the CDC7 inhibitor as both a monotherapy and combination.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.